Amics Therapeutics, based in Cranbury, NJ (USA), focuses on finding treatments for a range of devastating and rare and orphan diseases. Its lead biologics program is ATB200/AT2221, a uniquely engineered Pompe disease enzyme replacement therapy that will be administered in combination with a pharmacological chaperone and tested in multiple human …
We’ve got preferences and so do you
Is it possible for a global CRO to improve – and even reshape – today’s drug development industry? We think so. We work with people like you to offer unique perspectives at every stage of development – from early phase development to clinical trials and commercialization. But enough about us. …